STAT+: CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment
Results from a late-stage clinical trial released late Friday by the drug maker CytoDyn showed its experimental antibody leronlimab failed to improve the survival of patients hospitalized with severe, life-threatening cases of Covid-19.
Instead of acknowledging the negative outcome of the Phase 3 clinical trial, however, CytoDyn issued two statements over the weekend claiming results spun from a small slice of patients were positive and warranted approval as a treatment for Covid-19.
Continue to STAT+ to read the full story…
